BRCA1 and breast carcinoma: Notably, in a double-blind phase III trial, the subgroup analysis showed that the addition of veliparib to a carboplatin/paclitaxel regimen resulted in durable benefit with prolonged mPFS compared to the placebo/chemotherapy arm for all subgroups defined by homologous recombination (HR) or breast cancer susceptibility genes (BRCA1/2) status (HR + : 13.0 vs. 12.5 months, P = 0.013; TNBC: 16.6 vs. 14.1 months, P = 0.052; germline mutation in BRCA1 (gBRCA1): 14.2 vs. 12.6 months, P = 0.073; and gBRCA2: 14.6 vs. 12.6 months, P = 0.021) [57].